PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening

Human epidermal growth factor receptor (EGFR) 2 (HER2) is overexpressed/amplified in about 25% of all breast cancers, and EGFR is overexpressed in up to 76% and amplified in up to 24% of triple-negative breast cancers (TNBC). Here, we aimed to identify inhibitors that may enhance the anti-tumor acti...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Jangsoon Lee, Huey Liu, Troy Pearson, Toshiaki Iwase, Jon Fuson, Alshad S. Lalani, Lisa D. Eli, Irmina Diala, Debu Tripathy, Bora Lim, Naoto T. Ueno
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	MDPI AG 2021-06-01
Reeks:	Biomedicines
Onderwerpen:	neratinib HER2-positive breast cancer triple-negative breast cancer RNAi screening synergistic effect
Online toegang:	https://www.mdpi.com/2227-9059/9/7/740
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!